Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.153233110.3389/fphar.2024.1532331PharmacologyCorrectionCorrigendum: (Pro)renin receptor aggravates myocardial pyroptosis in diabetic cardiomyopathy through AMPK-NLRP3 pathwayLi et al.10.3389/fphar.2024.1532331LiShengnan123ZhangJingjing123ZhaoYuewen3KangLi4JieHaipeng123*DongBo123*1Department of Cardiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China2National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China3Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China4Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom
Edited and reviewed by:Nirmal Parajuli, Henry Ford Health System, United States
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on (Pro)renin receptor aggravates myocardial pyroptosis in diabetic cardiomyopathy through AMPK-NLRP3 pathway by Li S, Zhang J, Zhao Y, Kang L, Jie H and Dong B (2024). Front. Pharmacol. 15:1453647. doi: 10.3389/fphar.2024.1453647(Pro)renin receptordiabetic cardiomyopathypyroptosisNLRP3AMPK (AMP-activated protein kinase)section-at-acceptanceCardiovascular and Smooth Muscle Pharmacology
In the published article, there was an error in Figure 7 as published. In Figures 7G, J the analysis diagram for LVEF was erroneously excluded and an incorrect E/A analysis diagram was inserted in its place. The corrected Figure 7 and its caption appear below.
The silencing of PRR reduces heart damage in DCM rats. (A–C) Immunohistochemistry staining was used to detect the level of Collagen Ⅰ, Collagen Ⅲ, TGF-β and corresponding quantitative analysis. Scale bar: 100 μm. (D) The Masson staining was used to measure the deposition of collagen fiber of rats and corresponding quantitative analysis. Scale bar: 100 μm. (E) The HE staining was used to observe the morphological changes of myocardial tissue. Scale bar: 100 μm. (F) The echocardiography was used to detect the change of cardiac function of rats. (G–J) Quantitative analysis of LVEF, LVESD, LVEDD, E/A ratio in rats. *P < 0.05, **P < 0.01, compared with the Control group; #P < 0.05, ##P < 0.01, compared with the Ad-SC-shRNA group.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.